Introduction
Erectile dysfunction (ED), the persistent inability to have or to sustain a penile erection sufficient for satisfactory sexual activity, is associated with complex physical, psychological and interpersonal issues involving the man and his partner. [1] [2] [3] Sildenafil, the first oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of ED was approved by the US Food and Drug Administration (FDA) in 1998. 4 Subsequently, in 2003, vardenafil and tadalafil, two other PDE5 inhibitors, also received approval by the FDA as safe and effective treatments for ED. 5, 6 Men who respond successfully to treatment for ED report improved quality of life (QOL), 7, 8 yet simply restoring erectile function does not necessarily re-establish an intimate sexual relationship with a partner. [9] [10] [11] Even the most effective treatments can be diminished by an array of psychosocial issues involving the patient, the partner and their relationship. 12, 13 It has been shown that approximately 50% of patients discontinue PDE5 inhibitor therapy. 14 Reasons for discontinuation of ED treatments include lack of efficacy, weak sexual desire, fear of side effects, cost, loss of confidence, fear of failure, unrealistic expectations, partner sexual dysfunction, atypical arousal patterns, poor health in the patient and/or partner, communication problems and relationship deterioration. 9, 15 Clinicians are often puzzled by the tenacity of the psychosocial barriers that interfere with effective use of PDE5 inhibitors. The authors offer a series of recommendations based on their extensive clinical experience as researchers and clinicians. Although some suggestions are presented anecdotally, many recommendations are augmented by the evidence for different properties of PDE5 inhibitors found in the existing literature.
Sildenafil, tadalafil and vardenafil all act by inhibiting PDE5; however, they differ in their selectivity, pharmacokinetic properties and tolerability profiles. [4] [5] [6] 16 The primary pharmacokinetic differences between the PDE5 inhibitors relate to half-life and duration of therapeutic action. Both sildenafil and vardenafil have half-lives of about 4-5 h. 4, 5, 17 There has been one recent report indicating a duration of action for sildenafil up to 12 h and another study with vardenafil showing comparable duration. 18, 19 Prospective clinical trials have shown that the half-life of tadalafil is 17.5 h and its erectogenic effects are sustained for up to 36 h. 6, [20] [21] [22] Shabsigh et al.'s 23 clinical trial data analysis alerted clinicians to patients' willingness (facilitated by tadalafil's extended duration of action) to initiate sexual experiences beyond the 4-h window frequently described in the literature.
Comprehending the potential interaction of PDE5 inhibitor agents and psychosocial variables can facilitate an optimized and well-maintained treatment. 24, 25 A PDE5 inhibitor with an extended duration of action may, in some men, minimize the possibility of premature discontinuation of treatment while simultaneously increasing patient/ partner satisfaction.
The impact of ED on the man, his partner and the couple
The man Restarting a sexual relationship after a period of extended abstinence may be a pressured and anxiety-provoking process. Although PDE5 inhibitors can help restore a man's erectile function and self-confidence, 26 for some men, use of the shorteracting agents 4, 5 results in pressure to perform within a limited timeframe, potentially creating a constellation of management and psychological problems. Planning, in and of itself, may create positive anticipation, but it may also create anxiety for both the man and his partner (e.g. 'Honey, I took the pill. We've got to make love by 10 o'clock'). For some men, use of shorter-acting agents may lead to 'clockwatching,' causing the man to become more anxious and frustrated in his attempt to complete sexual intercourse before the offset of the compound's duration of action. 25 For some, this anxiety is exacerbated by the thought of 'wasting the pill. ' For men, not in long-term relationships, there is uncertainty regarding when the next sexual encounter may occur (e.g. will a dinner date evolve into a sexual encounter). The capacity to pre-dose with an extended-duration pharmaceutical may reduce anxiety. Both single men and men in committed relationships may be disappointed by loss of an erection with a first attempt. Some men report success hours later when trying again. Although discussion of multiple sexual encounters (rare in reality) over 24 h permeates both professional and public dialogue, it is the capacity to be primed for a follow-up attempt subsequent to an initial disappointment, that is one of the greatest advantages of a longer-duration compound. Perhaps knowing that he can is more important to the man than actually making love multiple times. In contrast, some men worry that a partner will expect him to be hypersexual. 25 A number of individuals misunderstand the concept of extended duration of action. They erroneously presume a man might actually have an erection for the duration of the extended time, rather than recognizing that it is the capacity to obtain an erection that is potentiated. Additionally, some individuals will presume that an extended duration of action should allow for multiple erections and sexual experiences to occur regardless of other psychosocial and physiological factors. Although anecdotal discussions abound regarding an increased capacity for an additional episode for younger, healthier men, there is no evidence documenting these assertions to date regardless of a compound's half-life. It is also clear that such a capacity, if documented, might be perceived by some as an advantage, whereas others would see it negatively.
There are men without significant concerns or barriers regarding resumption, planning or timing of sexual activity. For these men, a shorter-duration medication may be preferred. Additionally, men with serious chronic illnesses may have concerns about a medication that is active in their bodies for a longer period of time than they feel is required. Finally, regardless of the issue of duration, treatment focused solely on the erection is likely to be unsuccessful if underlying partner issues or relationship dynamics are ignored. 27 The partner ED frequently has a negative impact on the partner's sexual function and QOL. 28 Partners also have significant impact on treatment success and/or treatment discontinuation. 29, 30 Unresolved partner issues may cause many patients to abandon their ED treatment despite the effectiveness of the drug. 31 Fortunately, many partners are skillful at facilitating a return to successful sexual activity. Yet, for a PDE5 inhibitor therapy to be most effective, it should allow the partner the same freedom from pressure and anxiety that it offers the patient. Clinical experience demonstrates that when the partner becomes aware that the man has ingested a PDE5 inhibitor, she too may become cognizant of the time constraints and may 'watch the clock,' perhaps feeling pressured to be available within the timeframe of the drug's period of effectiveness. 25 She may not have had a voice in his decision to take the PDE5 inhibitor and may resent having to be available. Additionally, she may not feel amorous at that point in time. Finally, it can place undue pressure on her to be available if her mood changes. With a longer window of opportunity, the partner Treatment of ED with PDE5 inhibitors ME Dunn et al may have freedom to say 'yes,' 'no' or 'later' depending on the situation and without the medication being 'wasted.' This pressure is captured in one woman's comment juxtaposing her husband's previous use of a shorter-acting PDE5 inhibitor versus his current longer-acting agent: 'With his old medication, I felt like I was on fertility drugs all over again. It was sex on demand! I like the freedom I feel now.' Additionally, when the patient has taken the longer-acting PDE5 inhibitor for treatment of ED, the partner may be aware of his erections during sleep or when cuddling, even on the next day. This can increase her sense of attractiveness, which may have been diminished by his avoidance of affection and sexuality when he developed ED. If he has taken the medication long before they are sexual together, psychologically, the woman may feel she is inspiring the erection rather than the erection being a direct response to a pill. This perception can make her feel more desired and attractive, which seems to be an important component of female sexuality.
Additionally, she can feel free to initiate during the extended duration of action, something not possible when her partner was taking a shorteracting compound. She knows that she can say either yes or no to her husband's initiation, as well as have the ability to initiate. This can allow her to feel that sex is more natural and spontaneous, as it used to be before the inception of the ED.
For some women, however, the idea that the partner is potentially capable of having sex more than once over 36 h is threatening. They resent their partner's using a medication that could make this possible. Reflecting that viewpoint, one woman stated, 'I'm not that interested in sex and want him to get it over with quickly.' These women often feel more comfortable with their partner's using a shorter-duration medication. Other women worry about the extended duration, fearing it places her partner at undue risk for side effects or drug interactions.
9,15
The couple Many men with ED avoid all forms of physical affection and intimacy toward their partners. 3, 12, 32 A man may fear failing, embarrassing himself or ultimately frustrating his partner. His partner may be reluctant to initiate sexual activity, sensing his hesitancy and fearing his disappointment if he fails once again. When the couple does try to make love, the focus is more often on the man getting and keeping an erection than on pleasure or shared love. The encounter is often rushed, and romance, sensuality and foreplay have fallen away. In these cases, the couple's satisfaction and emotional well being may have suffered. 12, 33 However, if time pressures are reduced, previous positive sexual and nonsexual patterns may emerge, and in many cases the nonsexual dynamics may be improved. 9 The couple has more time to focus on the processaffection, friendship, intimacy and foreplay -and all of the other aspects that may enhance the renewal of a satisfying sexual relationship.
For some couples, any effective PDE5 inhibitor resolves their sexual dysfunction. Couples who are comfortable with a shorter-duration medication tend to be those who have a defined sexual script and typically know when they will have sexual relations. Couples whose sexual script has historically included sexual encounters over a variety of times during the course of a week may be more comfortable and appreciative of the flexibility that a longerduration compound provides. If an interruption or minor crisis arises, the couple can take time to manage the situation or postpone their sexual plans. With a longer-acting compound, they can resume lovemaking hours later, or even the next day, when conditions are more favorable.
The clinician's role in ED management
In an effort to effectively manage sexual dysfunction problems, clinicians are likely to emphasize patient satisfaction as the most fundamental outcome of ED treatment. 34 It has been shown that 65% of prescriptions written in the United States for PDE5 inhibitors are from primary care clinicians. 35 Ideally, these clinicians will provide early encouragement to help couples select ED treatments to enhance emotional and physical intimacy and to identify those couples who may benefit most from a long-acting PDE5 inhibitor. For effective therapy, the clinician will need to recognize that more attention should be paid to the broader behavioral, psychological and relationship outcomes of ED that may be of significant concern to the patient and his partner. 3 Clinicians can help reduce associated anxiety by focusing on four primary factors when treating and counseling patients for ED: (1) normalizing each patient's anxiety, (2) instilling optimism, (3) giving the couple permission to try different approaches to resuming sexual activity 2 and (4) asking questions, such as, 'What did he/she used to like?' and 'What was your most successful way of initiating sex?' 25 Clinician awareness of individual differences both within and between couples will improve the quality of recommendations made for each couple's sexual recovery and can determine which medication might be used most effectively with the least change required to established sexual interactions. 15 To help alleviate performance anxiety, the clinician can recommend that the couple start incorporating romance and 'together time' outside of the bedroom. Many couples have lost touch with each other and need encouragement to redevelop the emotional closeness of the relationship. 12, 32 Because it is difficult to restart a sexual relationship, Treatment of ED with PDE5 inhibitors ME Dunn et al clinicians are encouraged to recommend a reintroduction of affectionate touch and reestablishment of sexual intimacy with or without intercourse. 25 Additionally, because postmenopausal women may have decreased vaginal lubrication because of estrogen loss, topical lubricants can be prescribed to add to the comfort and pleasure of sexual activity. 36 Clinicians can also offer treatment choices to their patients and provide an unbiased, fair-balanced description of treatment options, including their expected clinical benefits based on the pharmacokinetics, clinical studies and prescribing experience. This interaction will enhance clinicianpatient relationships, minimize psychosocial obstacles and improve compliance. 15 Psychosocial factors between the patient and partner and their established sexual patterns and habits may suggest a particular drug based on pharmacokinetic profile. 24 Some clinicians have expressed concern that the potential side effects of a longer-acting medication may equate with the longer duration of action. Evidence to date suggests that, in the vast majority of patients, the duration of side effects does not seem to mirror the duration of action. 10, 16, 23, [37] [38] [39] [40] Clinicians may also be concerned about the possibility of extended drug-drug interactions with an extended-duration medication. This concern may be particularly important when a physician is managing a patient with cardiovascular disease (CVD). Of particular concern would be the patient with CVD who experiences chest pain and who may have access to nitroglycerin. Yet, all PDE5 inhibitors as a class of agents are contraindicated with organic nitrates. [4] [5] [6] These legitimate concerns may be reassured by clinicians managing ED for patients with CVD by following the guidelines recommended by the second Princeton Conference on Cardiovascular Safety and ED and supported by the American College of Cardiology. 41 The partner interview can help determine pharmaceutical selection based on analysis of the couple's relationship dynamics. Clinicians are encouraged to provide patient education to patients and their partners and to involve both parties in treatment decisions whenever possible. A continuing dialogue with patients is critical to facilitate success and prevent relapse. The numerous psychosocial issues previously discussed may prevent compliance. These issues are important in differentiating treatment nonresponders from treatment failures and to enhance clinical outcomes and success rates. Early failures can be reframed into learning experiences that may eventually lead to success. 15 Regular office follow-up is necessary to optimize the efficacy and safety of oral ED therapy. Patient follow-up visits provide an opportunity for the clinician to monitor side effects, determine whether medication is being used correctly, provide reinstruction if necessary, ask about the couple's satisfaction with treatment and assess the couple's overall health and relationship status. 13, [42] [43] [44] In general, the concept of relapse prevention has not been incorporated into sexual medicine, yet sexual dysfunction is recognized as a progressive disease in terms of underlying organic pathology, which may play a role in altering the threshold for response and the potential re-emergence of ED. 15, 24 To summarize, the main areas of therapeutic focus when a couple confers with their clinician and attempts to re-establish their sexual relationship with ED treatment are: 15 Identify what the couple's established sexual patterns and habits were before the onset of ED. Assess relationship issues that may preclude treatment success. Discuss treatment selection with the patient and partner. Recognize the need for follow-up appointments.
Conclusion
PDE5 inhibitors, as a class of medications, are safe and effective in treating ED. The choice of PDE5 inhibitor that is recommended to couples for restoration of erectile function is very important, perhaps crucial, to the success of treatment. To be truly effective, management of ED must address not only erectile function but also patient and partner satisfaction and the couple's sexual relationship. The experience of ED may have disrupted the couple's sexual equilibrium and made them vulnerable to feelings of anxiety and time pressure. The availability of PDE5 inhibitors with different durations of action allows the clinician to optimize a potential match between a couple's need and the pharmacokinetics of the compound.
